Ipsen S.A. (EPA: IPN)
France
· Delayed Price · Currency is EUR
108.60
-0.50 (-0.46%)
Dec 24, 2024, 2:01 PM CET
Ipsen Revenue
Ipsen had revenue of 1.75B EUR in the half year ending June 30, 2024, with 16.95% growth. This brings the company's revenue in the last twelve months to 3.44B, up 6.71% year-over-year. In the year 2023, Ipsen had annual revenue of 3.31B with 4.75% growth.
Revenue (ttm)
3.44B
Revenue Growth
+6.71%
P/S Ratio
2.62
Revenue / Employee
645.09K
Employees
5,325
Market Cap
8.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.31B | 150.00M | 4.75% |
Dec 31, 2022 | 3.16B | 407.80M | 14.84% |
Dec 31, 2021 | 2.75B | 62.40M | 2.32% |
Dec 31, 2020 | 2.69B | -6.60M | -0.25% |
Dec 31, 2019 | 2.69B | 344.40M | 14.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 48.45B |
EssilorLuxottica Société anonyme | 25.83B |
Sartorius Stedim Biotech S.A. | 2.74B |
bioMérieux S.A. | 3.81B |
Eurofins Scientific SE | 6.72B |
Virbac SA | 1.34B |
Ramsay Générale de Santé SA | 5.01B |
Vetoquinol SA | 537.47M |
Ipsen News
- 4 weeks ago - Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions - Seeking Alpha
- 2 months ago - Ipsen S.A. reports Q3 results; raises FY24 guidance - Seeking Alpha
- 2 months ago - Eton Pharmaceuticals to buy Increlex product from Ipsen - Seeking Alpha
- 3 months ago - Ipsen's Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease - Benzinga
- 3 months ago - Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade - Benzinga
- 3 months ago - Employee of French drugmaker Ipsen to plead guilty to US insider trading - Reuters
- 5 months ago - Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - GlobeNewsWire
- 7 months ago - Annual General Meeting of Ipsen S.A. held on 28 May 2024 - GlobeNewsWire